• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Renovaro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    7/14/25 9:18:41 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RENB alert in real time by email
    false 0001527728 0001527728 2025-07-14 2025-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): July 14, 2025

     

    RENOVARO INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38751   45-2259340
    (State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
    of incorporation)       Identification No.)

     

    2080 Century Park East, Suite 906

    Los Angeles, CA 90067

     (Address of principal executive offices)

     

    +1 (305) 918-1980

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
    Common Stock, par value $0.0001 per share   RENB   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

     

    On July 7, 2025, Renovaro Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5620(a), which requires that listed companies hold an annual meeting of shareholders no later than one year after the end of their fiscal year.

     

    The Company did not hold its annual meeting of shareholders within twelve months of the end of its fiscal year ended June 30, 2024, and therefore did not satisfy this requirement. Pursuant to Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days from the date of the Notice to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the fiscal year end, or until December 29, 2025, to regain compliance.

     

    The Company is working diligently to submit a plan of compliance within the required timeframe and intends to hold its annual meeting of shareholders as soon as practicable to regain compliance with Nasdaq’s continued listing standards.

     

    This notice does not immediately affect the listing or trading of the Company’s common stock on Nasdaq. However, if the Company fails to timely submit a compliance plan or if Nasdaq does not accept the Company’s plan, the Company’s common stock may be subject to delisting.

     

    The Company intends to monitor its compliance with the applicable Nasdaq Listing Rules and will take all necessary steps to maintain its Nasdaq listing.

     

    Forward – Looking Statements

    This Current Report on Form 8-K contains forward-looking statements that involve risks and uncertainties, including statements regarding the Company’s intent to submit a compliance plan and hold its annual meeting. Actual results may differ materially from the results predicted or implied. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to the Company’s ability to meet Nasdaq’s requirements, the Company’s financial position, and other factors disclosed in the Company’s filings with the Securities and Exchange Commission.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      RENOVARO INC.
       
      By: /s/ David Weinstein
        Name: David Weinstein
    Title: Chief Executive Officer

     

    Date: July 14, 2025 

     

     

     

    Get the next $RENB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RENB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RENB
    SEC Filings

    View All

    Renovaro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - RENOVARO INC. (0001527728) (Filer)

    8/6/25 11:51:40 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Renovaro Inc.

    DEF 14A - RENOVARO INC. (0001527728) (Filer)

    7/30/25 1:08:53 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Renovaro Inc. filed SEC Form 8-K: Leadership Update

    8-K - RENOVARO INC. (0001527728) (Filer)

    7/25/25 5:13:37 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RENB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner William Anderson Wittekind disposed of 350,000 shares, decreasing direct ownership by 9% to 3,353,878 units (SEC Form 4)

    4 - RENOVARO INC. (0001527728) (Issuer)

    3/12/25 8:12:50 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Van Tilburg Maurice was granted 250,000 shares (SEC Form 4)

    4 - RENOVARO INC. (0001527728) (Issuer)

    2/25/25 1:33:34 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Fuentes Nathen

    4 - RENOVARO INC. (0001527728) (Issuer)

    2/25/25 1:29:46 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RENB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks

    Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – There's a lot of big voices pushing for the AI revolution to make its mark, including a new plan from the U.S. Department of Commerce to address slow-to-adopt sectors like healthcare. The comes as part of US President Trump's paper, titled Winning the Race: AMERICA'S AI ACTION PLAN, which encourages setting up regulatory sandboxes, or regulation-free environments where AI can be tested in real world scenarios with heavy oversight. As the market evaluates the opportunities available, several tech and biotech companies are already moving toward

    7/29/25 3:01:00 PM ET
    $GEHC
    $HCTI
    $MDAI
    Medical Electronics
    Health Care
    EDP Services
    Technology

    Smart Healthcare Is Taking Over. Here's Where the Money's Headed

    Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI too

    6/10/25 11:13:00 AM ET
    $AMZN
    $GOOG
    $GOOGL
    Catalog/Specialty Distribution
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

    Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions" (Application No. 18/058,752). This patent strengthens Renovaro's AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse b

    6/3/25 9:15:00 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RENB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

    SC 13D/A - RENOVARO INC. (0001527728) (Subject)

    11/6/24 5:45:52 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

    SC 13D/A - RENOVARO INC. (0001527728) (Subject)

    10/24/24 8:57:01 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

    SC 13D/A - RENOVARO INC. (0001527728) (Subject)

    6/24/24 7:56:04 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RENB
    Leadership Updates

    Live Leadership Updates

    View All

    Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

    Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

    4/9/25 9:25:00 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

    Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicin

    2/26/25 1:25:00 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Renovaro Appoints Nathen Fuentes as Chief Financial Officer

    Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh. Nathen Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial l

    1/7/25 9:15:00 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care